FibroGen Financial Statements From 2010 to 2025

FGEN Stock  USD 0.45  0.01  2.27%   
FibroGen financial statements provide useful quarterly and yearly information to potential FibroGen investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on FibroGen financial statements helps investors assess FibroGen's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting FibroGen's valuation are summarized below:
Gross Profit
-15.2 M
Profit Margin
(0.68)
Market Capitalization
44.3 M
Enterprise Value Revenue
0.27
Revenue
180 M
We have found one hundred twenty available fundamental signals for FibroGen, which can be analyzed and compared to other ratios and to its rivals. Self-guided Investors are advised to verify FibroGen's prevailing fundamentals against the trend between 2010 and 2025 to make sure the company can sustain itself down the road.

FibroGen Total Revenue

179.8 Million

Check FibroGen financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among FibroGen's main balance sheet or income statement drivers, such as Depreciation And Amortization of 7.2 M, Interest Expense of 14.7 M or Selling General Administrative of 82.7 M, as well as many indicators such as Price To Sales Ratio of 1.7, Dividend Yield of 0.0337 or Days Sales Outstanding of 5.63. FibroGen financial statements analysis is a perfect complement when working with FibroGen Valuation or Volatility modules.
  
Check out the analysis of FibroGen Correlation against competitors.
To learn how to invest in FibroGen Stock, please use our How to Invest in FibroGen guide.

FibroGen Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets665.2 M487.1 M558.8 M
Slightly volatile
Short and Long Term Debt Total89.2 M153.4 M110.4 M
Pretty Stable
Other Current Liabilities200.7 M191.2 M84.2 M
Slightly volatile
Total Current Liabilities128.8 M250.3 M114.5 M
Slightly volatile
Other Liabilities147.1 M277.6 M137 M
Slightly volatile
Property Plant And Equipment Net89.5 M73.2 M109.5 M
Slightly volatile
Current Deferred Revenue10 M14.7 M8.6 M
Slightly volatile
Accounts Payable13 M20.7 M11.4 M
Slightly volatile
Cash239.8 M130.7 M191.5 M
Pretty Stable
Non Current Assets Total146.7 M82.8 M178.5 M
Slightly volatile
Non Currrent Assets Other6.5 M4.8 M7.7 M
Slightly volatile
Other Assets1.091.158.6 M
Pretty Stable
Long Term Debt46.3 M64.7 M64.5 M
Slightly volatile
Cash And Short Term Investments404.9 M270.9 M323.3 M
Slightly volatile
Net Receivables26.7 M47.2 M23.9 M
Slightly volatile
Common Stock Total Equity716.1 K1.1 M651 K
Slightly volatile
Common Stock Shares Outstanding78.2 M111.9 M71.1 M
Slightly volatile
Short Term Investments165.1 M140.2 M131.8 M
Slightly volatile
Liabilities And Stockholders Equity665.2 M487.1 M558.8 M
Slightly volatile
Non Current Liabilities Total261.8 M423.3 M236.3 M
Slightly volatile
Other Current Assets19.5 M15.4 M16 M
Pretty Stable
Other Stockholder EquityB1.9 B880.3 M
Slightly volatile
Total Liabilities390.6 M673.6 M350.8 M
Slightly volatile
Property Plant And Equipment Gross305.6 M291 M147.4 M
Slightly volatile
Total Current Assets463.5 M381.3 M375.5 M
Slightly volatile
Short Term Debt20.2 M16.2 M16.1 M
Pretty Stable
Common Stock773.7 K1.1 M663.4 K
Slightly volatile
Property Plant Equipment86.7 M90.8 M107.4 M
Slightly volatile
Deferred Long Term Liabilities2.6 M2.7 M41.6 M
Slightly volatile
Long Term Investments4.5 M4.8 M78 M
Slightly volatile
Short and Long Term Debt124.5 M132.3 M115.8 M
Slightly volatile
Noncontrolling Interest In Consolidated Entity21.3 M23 M19.8 M
Slightly volatile
Long Term Debt Total79 M50 M87.9 M
Slightly volatile
Capital Surpluse1.2 B1.7 BB
Slightly volatile
Additional Paid In Capital727 M1.3 B749.3 M
Slightly volatile
Non Current Liabilities Other122.8 M82.8 M81.8 M
Slightly volatile
Capital Lease Obligations65.1 M72.6 M85.8 M
Slightly volatile
Net Working Capital97.4 M102.5 M496.7 M
Slightly volatile
Capital StockM1.1 M905.1 K
Slightly volatile

FibroGen Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization7.2 M11.4 M6.8 M
Slightly volatile
Interest Expense14.7 M14 M9.2 M
Very volatile
Selling General Administrative82.7 M143.7 M72.9 M
Slightly volatile
Total Revenue179.8 M169.9 M152.7 M
Slightly volatile
Gross Profit174.1 M148.2 M147.1 M
Slightly volatile
Other Operating Expenses324.5 M494 M284 M
Slightly volatile
Research Development235.9 M325.3 M205.2 M
Slightly volatile
Cost Of Revenue16.1 M17 M92.5 M
Slightly volatile
Total Operating Expenses317.6 M457.8 M276.7 M
Slightly volatile
Minority Interest15.4 M17.3 M18.9 M
Slightly volatile
Interest Income9.1 M10.2 M8.3 M
Pretty Stable
Reconciled Depreciation14.5 M12.4 M10.1 M
Slightly volatile
Non Operating Income Net Other805.6 K906.3 K988.1 K
Slightly volatile

FibroGen Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation46.1 M58.4 M38.5 M
Slightly volatile
Begin Period Cash Flow231.1 M179.1 M185.5 M
Slightly volatile
Depreciation10.9 M11.4 M9.5 M
Slightly volatile
Capital Expenditures2.8 M2.9 M7.7 M
Slightly volatile
End Period Cash Flow239.8 M130.7 M191.5 M
Pretty Stable
Change To Netincome62 M76.7 M49.4 M
Slightly volatile
Change To Liabilities1.5 M1.6 M26.1 M
Slightly volatile
Issuance Of Capital Stock63.5 M60.5 M32.5 M
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio1.71.788411.1448
Slightly volatile
Dividend Yield0.03370.03790.0413
Slightly volatile
Days Sales Outstanding5.635.92758.128
Very volatile
Stock Based Compensation To Revenue0.890.85130.2986
Slightly volatile
Capex To Depreciation0.09390.09880.832
Pretty Stable
EV To Sales0.07990.084110.4734
Slightly volatile
Inventory Turnover0.330.410.2695
Slightly volatile
Days Of Inventory On Hand470724405
Slightly volatile
Payables Turnover1.151.2119.6689
Slightly volatile
Sales General And Administrative To Revenue0.230.270.2863
Very volatile
Average Inventory3.3 M3.1 M1.5 M
Slightly volatile
Research And Ddevelopement To Revenue3.393.23051.5468
Slightly volatile
Capex To Revenue0.00850.0090.0479
Pretty Stable
Cash Per Share0.480.50464.0826
Very volatile
Days Payables Outstanding312313333
Slightly volatile
Current Ratio1.41.47413.6231
Pretty Stable
Receivables Turnover64.6661.582114.959
Slightly volatile
Capex Per Share0.00250.00270.1107
Very volatile
Revenue Per Share0.280.29612.1787
Slightly volatile
Debt To Assets0.490.460.2467
Very volatile
Operating Cycle5.635.927388
Slightly volatile
Days Of Payables Outstanding312313333
Slightly volatile
Ebt Per Ebit1.221.01961.1268
Slightly volatile
Quick Ratio1.381.45053.5801
Pretty Stable
Net Income Per E B T1.10.99821.0064
Slightly volatile
Cash Ratio0.360.37872.0154
Pretty Stable
Days Of Inventory Outstanding470724405
Slightly volatile
Days Of Sales Outstanding5.635.92758.128
Very volatile
Free Cash Flow Operating Cash Flow Ratio0.821.00191.0265
Very volatile
Fixed Asset Turnover1.261.631.4309
Slightly volatile
Debt Ratio0.490.460.2467
Very volatile
Price Sales Ratio1.71.788411.1448
Slightly volatile
Asset Turnover0.130.13810.2616
Slightly volatile

FibroGen Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap94.2 M99.2 M2.3 B
Slightly volatile
Enterprise Value156.2 M164.5 M1.9 B
Slightly volatile

FibroGen Fundamental Market Drivers

Forward Price Earnings61.3497
Cash And Short Term Investments235.6 M

FibroGen Upcoming Events

26th of February 2024
Upcoming Quarterly Report
View
13th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
26th of February 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About FibroGen Financial Statements

FibroGen investors utilize fundamental indicators, such as revenue or net income, to predict how FibroGen Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue14.7 M10 M
Total Revenue169.9 M179.8 M
Cost Of Revenue17 M16.1 M
Stock Based Compensation To Revenue 0.85  0.89 
Sales General And Administrative To Revenue 0.27  0.23 
Research And Ddevelopement To Revenue 3.23  3.39 
Capex To Revenue 0.01  0.01 
Revenue Per Share 0.30  0.28 
Ebit Per Revenue(5.08)(4.82)

Pair Trading with FibroGen

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if FibroGen position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in FibroGen will appreciate offsetting losses from the drop in the long position's value.

Moving against FibroGen Stock

  0.33DVAX Dynavax TechnologiesPairCorr
The ability to find closely correlated positions to FibroGen could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace FibroGen when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back FibroGen - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling FibroGen to buy it.
The correlation of FibroGen is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as FibroGen moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if FibroGen moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for FibroGen can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether FibroGen offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of FibroGen's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Fibrogen Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Fibrogen Stock:
Check out the analysis of FibroGen Correlation against competitors.
To learn how to invest in FibroGen Stock, please use our How to Invest in FibroGen guide.
You can also try the Portfolio File Import module to quickly import all of your third-party portfolios from your local drive in csv format.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of FibroGen. If investors know FibroGen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about FibroGen listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
0.536
Earnings Share
(1.23)
Revenue Per Share
1.81
Quarterly Revenue Growth
0.154
Return On Assets
(0.21)
The market value of FibroGen is measured differently than its book value, which is the value of FibroGen that is recorded on the company's balance sheet. Investors also form their own opinion of FibroGen's value that differs from its market value or its book value, called intrinsic value, which is FibroGen's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because FibroGen's market value can be influenced by many factors that don't directly affect FibroGen's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between FibroGen's value and its price as these two are different measures arrived at by different means. Investors typically determine if FibroGen is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, FibroGen's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.